Scientific News
VHH Antibody Repertoire to Phage Library Comparison
Project Summary Camelids such as llamas and alpacas produce conventional antibodies as well as heavy-chain only antibodies (HCAbs) from which the small, stable antigen-binding domain (VHH) can be extracted. Abterra Biosciences developed Reptor, a proprietary antibody...
Case Study: Reptor Biological vs Technical Replicates
Project Summary Next-generation sequencing of B cell populations (Rep-Seq) has become a powerful tool in immunology and antibody discovery. At Abterra Bio we developed Reptor, an integrated Rep-Seq sequencing and analysis service. A key goal of Reptor is to provide...
New Service: Alicanto for Antibody Discovery from Human Serum
We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our...
Case Study: Reptor Phage Enrichment
Project Summary Phage display is a powerful toolkit for antibody discovery and engineering. In this study, we used phage display to identify Cas9-binding single domain (VHH) antibodies. In addition to traditional colony picking, we used our Reptor immune repertoire...
Advantages of High-Throughput Hybridoma Sequencing with NGS
Having a diverse collection of leads at the beginning of your antibody development campaign is critical for downstream success. As we know well, the immune response to immunization often focuses on a small number of antibody families with highly similar CDR3s which...
Why Sequence My Antibody Protein?
Over the past decade of sequencing thousands of antibodies, we've discovered the top reasons to sequence your antibody protein.Top reasons to sequence my antibody 1. To protect my intellectual property through patents for regulatory application and antibody...
Case Study: Alicanto Discovers High Affinity Rabbit Antibodies to Detect Neurofibromin
Researchers at Infixion Bioscience are on a mission to develop new therapeutics for the “orphan disease” neurofibromatosis type 1, which is diagnosed at a rate 1 in 3000 live births, impacting millions across the globe. Neurofibromatosis type 1 is a genetic disorder...
Customer Spotlight: Dr. Matthew Burchill
Valens™ Rescues Antibody for Liver Disease ResearchDr. Matthew Burchill explains how Abterra Bio's technology, Valens rescued his antibody and enabled him to continue his research in chronic liver disease. "The sequencing provided is instrumental to our work as the...
Multi-Species Antibody Repertoire Comparison
A decade ago, in vivo antibody discovery relied heavily on wild-type mice. Today, it’s not uncommon to generate antibodies using a petting zoo of animals including chicken, goat, rabbit, llamas, alpacas, and humanized rodents. The immune responses of these animals...
Other Categories
Get In Touch